Plus: Management changes at Kymera, Arcutis and Merakris

Ipsen’s Iqirvo, Geron’s Rytelo among June highlights

Decisions from FDA due on a nasal naloxone and Sprycel competitor, among others

Plus: Pivotal closes $389M Partners Fund II and updates from Novo Nordisk Foundation, Mirum, Santhera, Arcutis and Checkpoint

Plus: BioMarin to sell gene therapy in Germany for $2M less than U.S. and updates from Arrivo, Verve, Arcutis, Boehringer, Phenomic 

Plus: Rocket parlays gene therapy update into $175M raise and updates from DalCor, Mironid, Crinetics, Shionogi, Hasten, Dewpoint and Orchid

Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé

Plus: Arcutis out-licenses Asia rights to skin drug and financings for Tango, Merus, Jinlan Gene Technology

$2.4B deal gives Lilly autoimmune programs that complement Taltz, and a platform to make more oral therapies

Plus updates from Alto, Union, AskBio-Recode, Phathom and more